OBJECTIVE: Information regarding the ideal length of hot flash trials is scarce. In the literature, hot flash trial durations have commonly varied from 4 to 12 weeks. This article is devoted to providing scientific data to better ascertain how long it is necessary to conduct hot flash trials with newer centrally acting agents. METHODS: Individual participant data were collected from all known published, through December 2007, randomized, placebo-controlled, double-blinded clinical trials regarding the use of newer antidepressants and gabapentin for hot flash relief. Trials that studied periods longer than 4 weeks were included for this project. Profile analysis was applied to the hot flash activity longitudinal data for each study individually, allowing a comparison of data collected for 6 to 12 treatment weeks versus data collected for only 4 treatment weeks. RESULTS: Ten studies were identified, five of them fulfilled the eligibility criteria for this investigation, three evaluating gabapentin, and two newer antidepressants. Flatness tests from a profile analysis did not provide any evidence that hot flash activity increased or decreased between week 4 and time periods up to 12 weeks. CONCLUSIONS: Changes in hot flash scores from newer antidepressants and gabapentin are apparent within 4 weeks of therapy. Available data indicate that hot flash treatment efficacy, compared with that of placebo, remains stable for up to 12 weeks of follow-up.
RCT Entities:
OBJECTIVE: Information regarding the ideal length of hot flash trials is scarce. In the literature, hot flash trial durations have commonly varied from 4 to 12 weeks. This article is devoted to providing scientific data to better ascertain how long it is necessary to conduct hot flash trials with newer centrally acting agents. METHODS: Individual participant data were collected from all known published, through December 2007, randomized, placebo-controlled, double-blinded clinical trials regarding the use of newer antidepressants and gabapentin for hot flash relief. Trials that studied periods longer than 4 weeks were included for this project. Profile analysis was applied to the hot flash activity longitudinal data for each study individually, allowing a comparison of data collected for 6 to 12 treatment weeks versus data collected for only 4 treatment weeks. RESULTS: Ten studies were identified, five of them fulfilled the eligibility criteria for this investigation, three evaluating gabapentin, and two newer antidepressants. Flatness tests from a profile analysis did not provide any evidence that hot flash activity increased or decreased between week 4 and time periods up to 12 weeks. CONCLUSIONS: Changes in hot flash scores from newer antidepressants and gabapentin are apparent within 4 weeks of therapy. Available data indicate that hot flash treatment efficacy, compared with that of placebo, remains stable for up to 12 weeks of follow-up.
Authors: Haeseong Park; Rui Qin; Thomas J Smith; Pamela J Atherton; Debra L Barton; Keren Sturtz; Shaker R Dakhil; Daniel M Anderson; Kathleen Flynn; Suneetha Puttabasavaiah; Nguyet Anh Le-Lindqwister; Gilbert D A Padula; Charles L Loprinzi Journal: Menopause Date: 2015-06 Impact factor: 2.953
Authors: Hadine Joffe; Katherine A Guthrie; Joseph Larson; Lee S Cohen; Janet S Carpenter; Andrea Z Lacroix; Ellen W Freeman Journal: Menopause Date: 2013-03 Impact factor: 3.310
Authors: William I Fisher; Aimee K Johnson; Gary R Elkins; Julie L Otte; Debra S Burns; Menggang Yu; Janet S Carpenter Journal: CA Cancer J Clin Date: 2013-01-25 Impact factor: 508.702
Authors: Ellen W Freeman; Katherine A Guthrie; Bette Caan; Barbara Sternfeld; Lee S Cohen; Hadine Joffe; Janet S Carpenter; Garnet L Anderson; Joseph C Larson; Kristine E Ensrud; Susan D Reed; Katherine M Newton; Sheryl Sherman; Mary D Sammel; Andrea Z LaCroix Journal: JAMA Date: 2011-01-19 Impact factor: 157.335
Authors: Julia K Prague; Rachel E Roberts; Alexander N Comninos; Sophie Clarke; Channa N Jayasena; Zachary Nash; Chedie Doyle; Deborah A Papadopoulou; Stephen R Bloom; Pharis Mohideen; Nicholas Panay; Myra S Hunter; Johannes D Veldhuis; Lorraine C Webber; Les Huson; Waljit S Dhillo Journal: Lancet Date: 2017-04-03 Impact factor: 79.321
Authors: Katherine M Newton; Susan D Reed; Katherine A Guthrie; Karen J Sherman; Cathryn Booth-LaForce; Bette Caan; Barbara Sternfeld; Janet S Carpenter; Lee A Learman; Ellen W Freeman; Lee S Cohen; Hadine Joffe; Garnet L Anderson; Joseph C Larson; Julie R Hunt; Kristine E Ensrud; Andrea Z LaCroix Journal: Menopause Date: 2014-04 Impact factor: 3.310
Authors: Roberto A Leon-Ferre; Paul J Novotny; Eric G Wolfe; Stephanie S Faubion; Kathryn J Ruddy; Daniel Flora; Christopher S R Dakhil; Kendrith M Rowland; Mark L Graham; Nguyet Le-Lindqwister; Thomas J Smith; Charles L Loprinzi Journal: JNCI Cancer Spectr Date: 2019-10-21